Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema

Noriko Umegaki, Masahiro Kira, Takahiko Horiuchi, Saori Itoi, Mamori Tani, Akinori Yokomi, Atsushi Tanemura, Hisaaki Miyahara, Michiyo Hatanaka, Hajime Kitamura, Etsuko Kitano, Ichiro Katayama

Research output: Contribution to journalArticle

Abstract

Hereditary angioedema (HAE) is a life-threatening disorder caused by deficiency or dysfunction of the C1 inhibitor protein. Patients with HAE are restricted in various medical treatments, which can induce an HAE attack. We herein report the first case of psoriatic arthritis (PSA) with type 1 HAE successfully treated with 25 mg of etanercept without HAE attack. Etanercept may represent a useful choice for treating patients with HAE accompanied by intractable PSA and rheumatoid arthritis (RA).

Original languageEnglish
Pages (from-to)928-930
Number of pages3
JournalModern Rheumatology
Volume22
Issue number6
DOIs
Publication statusPublished - 2012 Nov
Externally publishedYes

Fingerprint

Hereditary Angioedema Types I and II
Hereditary Angioedemas
Psoriatic Arthritis
Complement C1 Inhibitor Protein
Rheumatoid Arthritis
Etanercept

Keywords

  • Biological agent
  • Etanercept
  • Hereditary angioedema
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema. / Umegaki, Noriko; Kira, Masahiro; Horiuchi, Takahiko; Itoi, Saori; Tani, Mamori; Yokomi, Akinori; Tanemura, Atsushi; Miyahara, Hisaaki; Hatanaka, Michiyo; Kitamura, Hajime; Kitano, Etsuko; Katayama, Ichiro.

In: Modern Rheumatology, Vol. 22, No. 6, 11.2012, p. 928-930.

Research output: Contribution to journalArticle

Umegaki, N, Kira, M, Horiuchi, T, Itoi, S, Tani, M, Yokomi, A, Tanemura, A, Miyahara, H, Hatanaka, M, Kitamura, H, Kitano, E & Katayama, I 2012, 'Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema', Modern Rheumatology, vol. 22, no. 6, pp. 928-930. https://doi.org/10.1007/s10165-012-0604-2
Umegaki, Noriko ; Kira, Masahiro ; Horiuchi, Takahiko ; Itoi, Saori ; Tani, Mamori ; Yokomi, Akinori ; Tanemura, Atsushi ; Miyahara, Hisaaki ; Hatanaka, Michiyo ; Kitamura, Hajime ; Kitano, Etsuko ; Katayama, Ichiro. / Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema. In: Modern Rheumatology. 2012 ; Vol. 22, No. 6. pp. 928-930.
@article{29a193c7e6c2415fa9120a504d9cea09,
title = "Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema",
abstract = "Hereditary angioedema (HAE) is a life-threatening disorder caused by deficiency or dysfunction of the C1 inhibitor protein. Patients with HAE are restricted in various medical treatments, which can induce an HAE attack. We herein report the first case of psoriatic arthritis (PSA) with type 1 HAE successfully treated with 25 mg of etanercept without HAE attack. Etanercept may represent a useful choice for treating patients with HAE accompanied by intractable PSA and rheumatoid arthritis (RA).",
keywords = "Biological agent, Etanercept, Hereditary angioedema, Psoriatic arthritis",
author = "Noriko Umegaki and Masahiro Kira and Takahiko Horiuchi and Saori Itoi and Mamori Tani and Akinori Yokomi and Atsushi Tanemura and Hisaaki Miyahara and Michiyo Hatanaka and Hajime Kitamura and Etsuko Kitano and Ichiro Katayama",
year = "2012",
month = "11",
doi = "10.1007/s10165-012-0604-2",
language = "English",
volume = "22",
pages = "928--930",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema

AU - Umegaki, Noriko

AU - Kira, Masahiro

AU - Horiuchi, Takahiko

AU - Itoi, Saori

AU - Tani, Mamori

AU - Yokomi, Akinori

AU - Tanemura, Atsushi

AU - Miyahara, Hisaaki

AU - Hatanaka, Michiyo

AU - Kitamura, Hajime

AU - Kitano, Etsuko

AU - Katayama, Ichiro

PY - 2012/11

Y1 - 2012/11

N2 - Hereditary angioedema (HAE) is a life-threatening disorder caused by deficiency or dysfunction of the C1 inhibitor protein. Patients with HAE are restricted in various medical treatments, which can induce an HAE attack. We herein report the first case of psoriatic arthritis (PSA) with type 1 HAE successfully treated with 25 mg of etanercept without HAE attack. Etanercept may represent a useful choice for treating patients with HAE accompanied by intractable PSA and rheumatoid arthritis (RA).

AB - Hereditary angioedema (HAE) is a life-threatening disorder caused by deficiency or dysfunction of the C1 inhibitor protein. Patients with HAE are restricted in various medical treatments, which can induce an HAE attack. We herein report the first case of psoriatic arthritis (PSA) with type 1 HAE successfully treated with 25 mg of etanercept without HAE attack. Etanercept may represent a useful choice for treating patients with HAE accompanied by intractable PSA and rheumatoid arthritis (RA).

KW - Biological agent

KW - Etanercept

KW - Hereditary angioedema

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=84870373481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870373481&partnerID=8YFLogxK

U2 - 10.1007/s10165-012-0604-2

DO - 10.1007/s10165-012-0604-2

M3 - Article

C2 - 22310967

AN - SCOPUS:84870373481

VL - 22

SP - 928

EP - 930

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -